Missed our World Preview webinar? Check it out on-demand to get the highlights from our panel as they discuss the latest pharma forecasts.| Evaluate
Dupixent hasn’t generated as much buzz as top-sellers like Keytruda or Ozempic, but the drug is boosting Sanofi’s earnings into the future.| PharmaVoice